 CHARLOTTESVILLE, VA ACCESSWIRE January 9, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received favorable opinions from the Finnish Medicines Agency FIMEA and National Committee on Medical Research Ethics TUKIJA to commence its Phase 3 study to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder AUD. Finland is the first of seven European countries in which we plan to open clinical sites as we conduct our AD04 Phase 3 trial in AUD subjects with certain target genotypes related to the serotonin transporter and receptor genes, which appeared to correlate to response to treatment with AD04 in the Phase 2b clinical trial, commented Monika Rogozinska, Chief Development Officer of Adial Pharmaceuticals. 